A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Clinical trial NCT06136741 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06136741
- Sponsor
- Nektar Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-15
- Primary completion
- 2025-05-06
- Enrollment
- 396
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.